- Home
- SBFM
SBFM
Sunshine Biopharma Inc.
as 03-31-2025 9:43am EST
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | FORT LAUDERDALE |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $15.00 | AVG Volume (30 days): | 31.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -26.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.90 - $266.00 | Next Earning Date: | 05-19-2025 |
| Revenue: | $32,959,491 | Revenue Growth: | 61.94% |
| Revenue Growth (this year): | 59.94% | Revenue Growth (next year): | 164.69% |
Latest Sunshine Biopharma Inc. News
SBFM Breaking Stock News: Dive into SBFM Ticker-Specific Updates for Smart Investing
TipRanks
6 days ago
Sunshine Biopharma signs agreement for rights to market two generic antibiotics
ACCESS Newswire
7 days ago
Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada
ACCESS Newswire
21 days ago
Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market
ACCESS Newswire
2 months ago
Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT
ACCESS Newswire
3 months ago
Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer
MT Newswires
3 months ago
Sunshine Biopharma Files $100 Million Mixed Shelf; Shares Down
ACCESSWIRE
4 months ago
Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus
ACCESSWIRE
4 months ago
Sunshine Biopharma Launches a New Generic Prescription Drug
Compare SBFM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SBFM Sunshine Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.